Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.

Literature DB >> 29871906

PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.

Panagiotis A Konstantinopoulos¹, Ursula A Matulonis².

Abstract

PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and BRCA-mutated (BRCAm) cancer treatment. Clin Cancer Res; 24(17); 4062-5. ©2018 AACRSee related article by Ison et al., p. 4066. ©2018 American Association for Cancer Research.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2018 PMID： 29871906 DOI： 10.1158/1078-0432.CCR-18-1314

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

Keyword Cloud
Cited

15 in total

1. N⁶-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.

Authors: Takeshi Fukumoto; Hengrui Zhu; Timothy Nacarelli; Sergey Karakashev; Nail Fatkhutdinov; Shuai Wu; Pingyu Liu; Andrew V Kossenkov; Louise C Showe; Stephanie Jean; Lin Zhang; Rugang Zhang
Journal: Cancer Res Date: 2019-04-09 Impact factor: 12.701

2. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.

Authors: Rashid Gabbasov; I Daniel Benrubi; Shane W O'Brien; John J Krais; Neil Johnson; Samuel Litwin; Denise C Connolly
Journal: Cancer Biol Ther Date: 2019-03-30 Impact factor: 4.742

Review 3. Biomarker-Guided Development of DNA Repair Inhibitors.

Authors: James M Cleary; Andrew J Aguirre; Geoffrey I Shapiro; Alan D D'Andrea
Journal: Mol Cell Date: 2020-05-26 Impact factor: 17.970

Review 4. DNA Repair: Translation to the Clinic.

Authors: E V Minten; D S Yu
Journal: Clin Oncol (R Coll Radiol) Date: 2019-03-12 Impact factor: 4.126

5. Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death.

Authors: Marwan Ibrahim Abdullah; Mohammed Najim Abed; Farhat Khanim; Alan Richardson
Journal: Sci Rep Date: 2019-07-03 Impact factor: 4.379

6. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.

Authors: Rachel M Hurley; Cordelia D McGehee; Ksenija Nesic; Cristina Correia; Taylor M Weiskittel; Rebecca L Kelly; Annapoorna Venkatachalam; Xiaonan Hou; Nicholas M Pathoulas; X Wei Meng; Olga Kondrashova; Marc R Radke; Paula A Schneider; Karen S Flatten; Kevin L Peterson; Marc A Becker; Ee Ming Wong; Melissa S Southey; Alexander Dobrovic; Kevin K Lin; Thomas C Harding; Iain McNeish; Christian A Ross; Jill M Wagner; Matthew J Wakefield; Clare L Scott; Paul Haluska; Andrea E Wahner Hendrickson; Larry M Karnitz; Elizabeth M Swisher; Hu Li; S John Weroha; Scott H Kaufmann
Journal: NAR Cancer Date: 2021-07-09

7. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer.

Authors: Judit Börcsök; Zsofia Sztupinszki; Raie Bekele; Sizhi P Gao; Miklos Diossy; Amruta S Samant; Kasia M Dillon; Viktoria Tisza; Sándor Spisák; Orsolya Rusz; Istvan Csabai; Helle Pappot; Zoë J Frazier; David J Konieczkowski; David Liu; Naresh Vasani; James A Rodrigues; David B Solit; Jean H Hoffman-Censits; Elizabeth R Plimack; Jonathan E Rosenberg; Jean-Bernard Lazaro; Mary-Ellen Taplin; Gopa Iyer; Søren Brunak; Rita Lozsa; Eliezer M Van Allen; Dávid Szüts; Kent W Mouw; Zoltan Szallasi
Journal: Clin Cancer Res Date: 2020-11-18 Impact factor: 13.801